Reading the full Wilsons report, its interesting that they believe NNZ-2591 - if successfull - could "cannibalise" the profitability of Trof, and overall reduce NEU and Acadia value...
"Neuren have been savvy in tacking on limited rights to NNZ-2591 to this agreement with Acadia.They have monetised this asset in two indications that were previously ‘dead’ in the sense that Neuren (or anyother NNZ-2591 licensee) was not able to develop NNZ-2591 for Rett or FXS given the non-compete clause inthe existing trofinetide agreement. Specifically, the agreement stated Neuren could not develop competingproducts to trofinetide in those two indications. NNZ-2591 is a competing/replacement product to trofinetidegiven its similarity of mechanism (targeting IGF-1 restoration). We had previously accepted that these twoindications were off the table for Neuren’s development program with NNZ-2591, focusing our valuation andresearch on the four neurodevelopmental disorders (NDDs) currently in Phase II trials (Phelan-McDermid,Angelmans, Pitt-Hopkins, Prader Willi syndromes)."
- Forums
- ASX - By Stock
- NEU
- Ann: Investor web conference presentation, 14 July 2023
Ann: Investor web conference presentation, 14 July 2023, page-36
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.71 |
Change
0.000(0.00%) |
Mkt cap ! $2.644B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 269 | $21.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.37 | 10 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 269 | 21.740 |
1 | 500 | 21.500 |
1 | 50 | 21.120 |
2 | 23031 | 21.000 |
2 | 6 | 20.910 |
Price($) | Vol. | No. |
---|---|---|
20.370 | 10 | 1 |
20.500 | 118 | 2 |
20.710 | 100 | 2 |
20.800 | 662 | 6 |
21.000 | 1500 | 1 |
Last trade - 13.00pm 23/05/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
Day chart unavailable